Derrick Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Derrick Lee has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Haibo Xu
Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People’s Hospital, First Affiliated Hospital of Shenzhen University, Shenzhen, China
12 shared publications - Jill Meisenhelder
Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California
12 shared publications - Tony Hunter
Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies
12 shared publications - Xue Wang
Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California
12 shared publications - Yuan Sui
Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California
12 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Report from PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway
Supplementary report addressing the cell line authentication and Mycoplasma testing
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Report from PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway
Supplementary report addressing the cell line authentication and Mycoplasma testing
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S21 from PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway
Supplementary Figure S1. Luminal urothelial cells show higher PIN1 expression levels. Supplementary Figure S2. PIN1 overexpression in normal immortalized SV-HUC-1 and RT4 huBLCA cells promotes cell proliferation, cell motility, invasion, migration and urothelium clearance. Supplementary Figure S3. PIN1 positively regulates T24 and 5637 cell proliferation and spheroid formation in vitro. Supplementary Figure S4. PIN1 positively regulates T24 and 5637 cell invasion, migration, cell motility and urothelium clearance in vitro. Supplementary Figure S5. Tumor masses derived from PIN1-KO T24, and 5637 cells show declining urothelial cell layers, and PIN1 promotes T24 cell tumor growth in vivo. Supplementary Figure S6. PIN1 promotes 5637 cell orthotopic tumor growth in vivo. Supplementary Figure S7. Treatment with the PIN1 specific inhibitor, sulfopin, lowers T24 cell proliferation and negatively regulates 5637 and T24 cell spheroid formation, cell motility, cell invasion and migration in vitro. Supplementary Figure S8. Sulfopin administration reduces urothelial cell layers in tumor masses derived from T24 and 5637 control cells and suppresses T24 cell tumor growth in vivo. Supplementary Figure S9. MB49 cells instilled through the urethra metastasize to distant organs, lung, and kidney. Supplementary Figure S10. Reducing Pin1 expression in organoids derived from primary mouse urothelial cells shows lower cell proliferation. Supplementary Figure S11. PIN1 positively affects cell cholesterol levels and regulates cholesterol metabolism–related gene signatures. Supplementary Figure S12. SREBP2, a crucial transcriptional factor, associates with PIN1 and promotes huBLCA cell proliferation. Supplementary Figure S13. Ablation of Pin1 in mouse MB49 bladder cancer cells reduces the cholesterol level and expression levels of SREBP2 and its downstream targets, HMGCS1 and MVD. Supplementary Figure S14. PIN1 enhances the DNA-binding activity of the SREBP2 transcription factor. Supplementary Figure S15. TNFα promotes JNK phosphorylation and activation, and the interaction between PIN1 and SREBP2. Supplementary Figure S16. JNK-mediated phosphorylation of Ser455 in SREBP2 is required for the interaction between PIN1 and SREBP2 in T24 cells. Supplementary Figure S17. PIN1 inhibition in SREBP2 S455A mutant re-expressing huBLCA cells slightly reduced the SREBP2 expression level compared to that of SREBP2 S455A mutant re-expressing cells. Supplementary Figure S18. The sulfopin PIN1 inhibitor treatment in SREBP2 S455A mutant re-expressing cells slightly reduced the cholesterol biosynthesis, bladder cancer cell proliferation and migration in vitro. Supplementary Figure S19. PIN1 knockout in SREBP2 S455A mutant re-expressing cells slightly reduced the cholesterol biosynthesis, bladder cancer cell proliferation and migration in vitro. Supplementary Figure S20. PIN1 knockout in SREBP2 S455A mutant re-expressing cells slightly reduced the 5637-cell tumor growth in vivo. Supplementary Fig. S21. The cholesterol biosynthesis pathway is affected by the combination therapy of sulfopin plus simvastatin.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S21 from PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway
Supplementary Figure S1. Luminal urothelial cells show higher PIN1 expression levels. Supplementary Figure S2. PIN1 overexpression in normal immortalized SV-HUC-1 and RT4 huBLCA cells promotes cell proliferation, cell motility, invasion, migration and urothelium clearance. Supplementary Figure S3. PIN1 positively regulates T24 and 5637 cell proliferation and spheroid formation in vitro. Supplementary Figure S4. PIN1 positively regulates T24 and 5637 cell invasion, migration, cell motility and urothelium clearance in vitro. Supplementary Figure S5. Tumor masses derived from PIN1-KO T24, and 5637 cells show declining urothelial cell layers, and PIN1 promotes T24 cell tumor growth in vivo. Supplementary Figure S6. PIN1 promotes 5637 cell orthotopic tumor growth in vivo. Supplementary Figure S7. Treatment with the PIN1 specific inhibitor, sulfopin, lowers T24 cell proliferation and negatively regulates 5637 and T24 cell spheroid formation, cell motility, cell invasion and migration in vitro. Supplementary Figure S8. Sulfopin administration reduces urothelial cell layers in tumor masses derived from T24 and 5637 control cells and suppresses T24 cell tumor growth in vivo. Supplementary Figure S9. MB49 cells instilled through the urethra metastasize to distant organs, lung, and kidney. Supplementary Figure S10. Reducing Pin1 expression in organoids derived from primary mouse urothelial cells shows lower cell proliferation. Supplementary Figure S11. PIN1 positively affects cell cholesterol levels and regulates cholesterol metabolism–related gene signatures. Supplementary Figure S12. SREBP2, a crucial transcriptional factor, associates with PIN1 and promotes huBLCA cell proliferation. Supplementary Figure S13. Ablation of Pin1 in mouse MB49 bladder cancer cells reduces the cholesterol level and expression levels of SREBP2 and its downstream targets, HMGCS1 and MVD. Supplementary Figure S14. PIN1 enhances the DNA-binding activity of the SREBP2 transcription factor. Supplementary Figure S15. TNFα promotes JNK phosphorylation and activation, and the interaction between PIN1 and SREBP2. Supplementary Figure S16. JNK-mediated phosphorylation of Ser455 in SREBP2 is required for the interaction between PIN1 and SREBP2 in T24 cells. Supplementary Figure S17. PIN1 inhibition in SREBP2 S455A mutant re-expressing huBLCA cells slightly reduced the SREBP2 expression level compared to that of SREBP2 S455A mutant re-expressing cells. Supplementary Figure S18. The sulfopin PIN1 inhibitor treatment in SREBP2 S455A mutant re-expressing cells slightly reduced the cholesterol biosynthesis, bladder cancer cell proliferation and migration in vitro. Supplementary Figure S19. PIN1 knockout in SREBP2 S455A mutant re-expressing cells slightly reduced the cholesterol biosynthesis, bladder cancer cell proliferation and migration in vitro. Supplementary Figure S20. PIN1 knockout in SREBP2 S455A mutant re-expressing cells slightly reduced the 5637-cell tumor growth in vivo. Supplementary Fig. S21. The cholesterol biosynthesis pathway is affected by the combination therapy of sulfopin plus simvastatin.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway
Source data for all immunostaining images in this paper
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway
Source data for all immunostaining images in this paper
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway
Identities of functional pSer-Thr.Pro protein substrates of the PIN1 prolyl isomerase and its effects on downstream signaling in bladder carcinogenesis remain largely unknown. Phenotypically, we found that PIN1 positively regulated bladder cancer cell proliferation, cell motility, and urothelium clearance capacity in vitro and controlled tumor growth and potential metastasis in vivo. Mechanistically, we observed a negative enrichment of SREBP2-driven cholesterol metabolism pathways and a decrease in free/total cholesterol levels in PIN1-knockout bladder cancer cells. Moreover, we showed that PIN1 interacted with SREBP2 following its phosphorylation by the JNK MAP kinase at Ser455, which lies near the site-2 cleavage site that generates the active, nuclear form of SREBP2. Therapeutically, a combination of the covalent PIN1 inhibitor sulfopin and the HMGCoA reductase inhibitor simvastatin synergistically suppressed cell proliferation in vitro and tumor growth in vivo. Together, these findings emphasize that PIN1 can act as a driver and potential therapeutic target in bladder cancer.Significance:This study provides deeper insights into the regulatory role of the phospho–dependent prolyl isomerase PIN1 in bladder cancer. The identification of the link between PIN1 and SREBP2-mediated transcription and cholesterol biosynthesis offers the potential for developing novel therapeutic strategies for bladder cancer.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway
Identities of functional pSer-Thr.Pro protein substrates of the PIN1 prolyl isomerase and its effects on downstream signaling in bladder carcinogenesis remain largely unknown. Phenotypically, we found that PIN1 positively regulated bladder cancer cell proliferation, cell motility, and urothelium clearance capacity in vitro and controlled tumor growth and potential metastasis in vivo. Mechanistically, we observed a negative enrichment of SREBP2-driven cholesterol metabolism pathways and a decrease in free/total cholesterol levels in PIN1-knockout bladder cancer cells. Moreover, we showed that PIN1 interacted with SREBP2 following its phosphorylation by the JNK MAP kinase at Ser455, which lies near the site-2 cleavage site that generates the active, nuclear form of SREBP2. Therapeutically, a combination of the covalent PIN1 inhibitor sulfopin and the HMGCoA reductase inhibitor simvastatin synergistically suppressed cell proliferation in vitro and tumor growth in vivo. Together, these findings emphasize that PIN1 can act as a driver and potential therapeutic target in bladder cancer.Significance:This study provides deeper insights into the regulatory role of the phospho–dependent prolyl isomerase PIN1 in bladder cancer. The identification of the link between PIN1 and SREBP2-mediated transcription and cholesterol biosynthesis offers the potential for developing novel therapeutic strategies for bladder cancer.
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway
Source data for all immunostaining images in this paper
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway
Source data for all immunostaining images in this paper
- Open Access
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Report from PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway
Supplementary report addressing the cell line authentication and Mycoplasma testing
- 3 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Report from PIN1 Prolyl Isomerase Promotes Initiation and Progression of Bladder Cancer through the SREBP2-Mediated Cholesterol Biosynthesis Pathway
Supplementary report addressing the cell line authentication and Mycoplasma testing